Company intelligence / Profile preview

Sunstone Life Science Ventures

Ownership: Private
Development stage: Other

Overview

Since 2007 has supported over 45 life science companies. Portfolio companies have originated at least 20 approved products for major indications including diabetes (e.g., Zegalogue®), rare disease enzyme replacement therapies (e.g., Lamzede®), vaccines/adjuvants now used in COVID vaccines and more. Over 23 successful exits/IPOs completed from its funds to date.

Therapeutic areas: PulmonologyOncologyEndocrinologyRare DiseasesCardiovascularNeurologyInfectious Diseases
Modalities: Small moleculeBiologicMonoclonal antibodyEnzyme replacement therapyVaccinePeptidePeptide analogVaccine adjuvant technology
Industry: Investors

Partnerships

Co-investments with major pharma venture arms such as Roche Venture FundBoehringer Ingelheim Venture Fund

Beyond the preview

Go deeper on Sunstone Life Science Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sunstone Life Science Ventures.

Explore the full profile